3 undervalued stocks from the healthcare sector
Healthcare has been one of the sectors investors have turned their backs on over the past two years. Regulatory pressure, rising care costs, and uncertainty around public programs have pushed valuations of many companies to levels the market previously assigned to declining industries. A low multiple, however, means nothing by itself. What matters is whether the pessimism priced in exceeds the actual risks or, conversely, underestimates them.
Key points
Healthcare is one of the most overlooked parts of the market. For some companies, valuations have fallen to levels typical of declining industries.
Three cheap stocks, but three completely different reasons. What matters is whether the market is correctly pricing structural problems or has gone too far in its pessimism.
Common screeners can be very misleading, but not on Bulios. Earnings, cash, and free cash flow can look very different from economic reality.
A low P/E does not yet mean true undervaluation. With this trio, it is necessary to separate one-off problems from those that could affect results for several more years.
Where is the market pricing in an overly negative scenario? The difference between a temporary crisis and a structural problem could decide the future potential of these stocks.
The healthcare sector is today one of the most divided corners of the US stock market. While pharmaceutical companies with obesity drugs or medical technology makers trade at a high premium, health insurers, pharmacy benefit managers, and digital health platforms are valued at a deep discount to the broad market.
Rising healthcare utilization after the pandemic, cuts in state Medicaid programs, the end of expanded insurance subsidies under the Affordable Care Act, and political pressure on drug price intermediaries are reasons why not many investors are rushing into this sector.
It is precisely in such an environment that situations arise where the market prices in the worst-case scenario before it actually materializes. For a long-term investor, however, it is crucial to distinguish a temporary problem from a structural one. The three companies in this analysis represent three completely different types of undervaluation, and each requires a different way of reading the numbers. Which are they?